Obesity pharmacotherapy: What is next?

被引:43
|
作者
Colon-Gonzalez, Francheska [1 ,2 ]
Kim, Gilbert W. [1 ,3 ]
Lin, Jieru E. [1 ]
Valentino, Michael A. [1 ]
Waldman, Scott A. [1 ,4 ]
机构
[1] Thomas Jefferson Univ, Dept Pharmacol & Expt Therapeut, Philadelphia, PA 19107 USA
[2] Thomas Jefferson Univ, Waldman Lab, Philadelphia, PA 19107 USA
[3] Thomas Jefferson Univ, Mol Pharmacol & Struct Biol Program, Philadelphia, PA 19107 USA
[4] Thomas Jefferson Univ, Dept Med, Philadelphia, PA 19107 USA
关键词
Obesity; Anti-obesity drugs; Appetite; Metabolism; GLUCAGON-LIKE PEPTIDE-1; FOOD-INTAKE; PANCREATIC-POLYPEPTIDE; WEIGHT-LOSS; NEUROPEPTIDE-Y; BODY-WEIGHT; INSULIN THERAPY; ENERGY-INTAKE; GUT HORMONE; LEPTIN;
D O I
10.1016/j.mam.2012.10.005
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The increase in obesity in the Unites States and around the world in the last decade is overwhelming. The number of overweight adults in the world surpassed 1 billion in 2008. Health hazards associated with obesity are serious and include heart disease, sleep apnea, diabetes, and cancer. Although lifestyle modifications are the most straightforward way to control weight, a large portion of the population may not be able to rely on this modality alone. Thus, the development of anti-obesity therapeutics represents a major unmet medical need. Historically, anti-obesity pharmacotherapies have been unsafe and minimally efficacious. A better understanding of the biology of appetite and metabolism provides an opportunity to develop drugs that may offer safer and more effective alternatives for weight management. This review discusses drugs that are currently on the market and in development as anti-obesity therapeutics based on their target and mechanism of action. It should serve as a roadmap to establish expectations for the near future for anti-obesity drug development. (C) 2012 Elsevier Ltd. All rights reserved.
引用
收藏
页码:71 / 83
页数:13
相关论文
共 50 条
  • [1] Association of obesity and cardiovascular disease and progress in pharmacotherapy: what is next for obesity?
    Mallah, Manthar Ali
    Soomro, Tahmina
    Noreen, Sobia
    Ali, Mukhtiar
    Kafle, Akriti
    Khatoon, Nafeesa
    Naveed, Muhammad
    INTERNATIONAL JOURNAL OF REHABILITATION RESEARCH, 2023, 46 (01) : 14 - 25
  • [2] Pharmacotherapy for obesity: What you need to know
    Bersoux, Sophie
    Byun, Tina H.
    Chaliki, Swarna S.
    Poole, Kenneth G., Jr.
    CLEVELAND CLINIC JOURNAL OF MEDICINE, 2017, 84 (12) : 951 - 958
  • [3] Molecular network of obesity: what does it promise for pharmacotherapy?
    Myslobodsky, M.
    OBESITY REVIEWS, 2008, 9 (03) : 236 - 245
  • [4] Pharmacotherapy for Obesity
    Lisa L. Ioannides-Demos
    Joseph Proietto
    John J. McNeil
    Drugs, 2005, 65 : 1391 - 1418
  • [5] Pharmacotherapy for obesity
    Kim, Kyoung Kon
    JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, 2011, 54 (04): : 409 - 418
  • [6] Pharmacotherapy for Obesity
    Saunders, Katherine H.
    Shukla, Alpana P.
    Igel, Leon I.
    Kumar, Rekha B.
    Aronne, Louis J.
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2016, 45 (03) : 521 - +
  • [7] Pharmacotherapy for Obesity
    Krandick, G.
    MONATSSCHRIFT KINDERHEILKUNDE, 2017, 165 (03) : 193 - 193
  • [8] Pharmacotherapy for obesity
    Neff L.M.
    Aronne L.J.
    Current Atherosclerosis Reports, 2007, 9 (6) : 454 - 462
  • [9] Pharmacotherapy of obesity
    Finer, N
    BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 16 (04) : 717 - 742
  • [10] Pharmacotherapy of Obesity
    Derwahl, K. -M.
    AKTUELLE ERNAHRUNGSMEDIZIN, 2008, 33 (01): : 21 - 25